Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Advanced unresectable or metastatic/intermediate/high grade soft tissue sarcoma
• Age ≥ 18 years at the time of enrollment
• Initiating first line systemic therapy for advanced/metastatic disease (treatment naïve for advanced/metastatic disease)
• Participants who have not yet initiated first line systemic therapy: expected to initiate front-line therapy within 4 weeks of initiating metformin
• Participants who have previously initiated first line systemic therapy: No more than 4 weeks from initiation of first line systemic therapy
• Adequate performance status (PS) defined as ECOG PS = 0-2
• Adequate renal function
• Adequate liver function
• Individuals of childbearing potential (ICBP) must have a negative serum pregnancy test within 7 days prior to enrollment. NOTE: Individuals who may become pregnant are considered to have childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are postmenopausal (at least 12 consecutive months with no menses without an alternative medical cause). Metformin is known to be excreted in breast milk and should not be used by nursing mothers.
• ICBP and partners of ICBP must not be expecting to conceive and be willing to use a highly effective contraceptive method (i.e., achieves a failure rate of <1% per year when used consistently and correctly) from the time of informed consent until 30 days after study treatment discontinuation.
• Individuals who are having sexual relationships in which their partners may become pregnant must be willing to use condoms from the time of informed consent until 30 days after study treatment discontinuation. For a non-pregnant ICBP partner, contraception recommendations should also be considered.
• Ability to ingest oral medications

You cannot join if

• Already prescribed and taking metformin at time of diagnosis of advanced unresectable or metastatic disease
• Planned enrollment on a treatment clinical trial for first line therapy
• Breastfeeding within the duration of anticipated study treatment. NOTE: breast milk cannot be stored for future use while the mother is being treated on study.
• History of acute or chronic metabolic acidosis including diabetic ketoacidosis, with or without coma.
• Participants previously diagnosed with an additional malignancy must be disease-free for at least five years prior to enrollment. Exceptions include ductal carcinoma in situ (DCIS), basal cell or squamous cell skin cancer and in situ cervical or bladder cancer.
• Treatment with any investigational drug within 14 days prior to day 1 of treatment
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin. Participants receiving any medications or substances that are inhibitors or inducers of CYP450 enzyme(s) are ineligible. Lists including medications and substances known or with the potential to interact with the specified CYP450 enzyme(s) isoenzymes. Please refer to https://drug-interactions.medicine.iu.edu/MainTable.aspx for the most current information.
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure requiring pharmacologic treatment, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator.
• Patients with known brain or active central nervous system (CNS) metastases.

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

extended release metformin hydrochloride. An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin, with antihyperglycemic and potential prostate-cancer protective and antineoplastic activities. Upon oral administration, metformin targets and inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. This lowers blood glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. It also reduces cyclin D1. This inhibits cancer cell proliferation. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Also, metformin reduces hyperinsulinemia which may contribute to an anti-tumor effect. Metformin may increase the prostate-specific antigen (PSA) doubling time and may lower serum PSA levels. NCI Drug Dictionary

Treatments listed in the registry

• Metformin Hydrochloride ER (Drug): Participants will initially take 1000mg ER of metformin by mouth daily for 14 days, in combination with physician directed SOC systemic therapy for advanced unresectable or metastatic STS.

Na · Single Group · masking: None

Main goals

• Number of participants surviving at 12 months (From date of metformin start to date of death, or censored at 12 months, whichever occurred first.)

Other goals

• Overall survival (OS)
• Cancer specific survival

Planned enrollment: 50 (estimated).

• Levine Cancer Institute, Charlotte, North Carolina
• Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT07291297
• NCI Drug Dictionary: C29251

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Jul 22, 2026. Public record; not medical advice.